Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Coadminstration of L. Major Amastigote Class I Nuclease (Rlmacin) With Lpd Nanoparticles Delays the Progression of Skin Lesion and the L. Major Dissemination to the Spleen in Balb/C Mice-Based Experimental Setting Publisher Pubmed



Fakhraee F1 ; Badiee A1 ; Alavizadeh SH1 ; Jalali SA2 ; Chavoshian O1 ; Khamesipour A3 ; Mahboudi F4 ; Jaafari MR5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Nanotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
  2. 2. Department of Immunology, Medical School, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. 3. Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Biotechnology Department, Pasteur Institute of Iran, Tehran, Iran
  5. 5. Biotechnology Research Center, Nanotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Source: Acta Tropica Published:2016


Abstract

Human cutaneous leishmaniasis is a disease caused by eukaryotic single-celled Leishmania species, the developmental program of which relies upon blood-feeding adult female sand flies and their dominant mammal blood sources, namely wild rodents in area where human beings exert more or less transient activities. The recourse to model rodents - namely laboratory mice such as C57BL/6 mice - has allowed extracted the immune signatures that account for the healing of the transient cutaneous lesion that develops at the site where Leishmania major promastigotes were delivered. Indeed, if the latter mice are exposed to a second inoculum of L. major promastigotes, no lesion will develop in the secondary skin site remodeled as a niche for a low size intracellular L. major amastigote population. Moreover, IFN-γ dominates over IL-10 in the supernatant of cultures of PBMCs -prepared from blood sampled from human beings who healed from a cutaneous lesion- and incubated with L. major class I Nuclease LmaCIN, a protein highly expressed in the cell-cycling amastigote population which is dominant by macrophages. Altogether, these datasets were strong incentive to promote research aimed to design and monitor efficacy of L. major amastigote protein-based vaccines in pre-clinical settings. Using L. major enzyme class I nuclease (LmaCIN) expressed in the L. major cell-cycling amastigote population hosted by macrophages, BALB/c mice were immunized three times with either rLmaCIN plus LPD nanoparticles (LPD-rLmaCIN), or rLmaCIN-CpG DNA or free rLmaCIN and dextrose. The following parameters: footpad swelling, splenic L. major load, L. major binding IgGs and cytokine profiles of rLmaCIN- reactive T lymphocytes were then compared. Once coadminstered with LPD, rLmaCIN allow BALB/c mice to display delayed onset of skin lesion at the challenge inoculation site and delayed L. major dissemination from the challenged site to the spleen. Thus, the LPD-rLmaCIN is shown to display some promising features out of three formulations inoculated to the BALB/c mouse immunization. © 2016 Elsevier B.V.
Experts (# of related papers)
Other Related Docs
9. Potential Biomarkers of Immune Protection in Human Leishmaniasis, Medical Microbiology and Immunology (2021)
10. Delivery Systems for Leishmania Vaccine Development, Expert Review of Vaccines (2016)
20. Vaccines for Preventing Cutaneous Leishmaniasis, Cochrane Database of Systematic Reviews (2018)
24. Unraveling the Role of Natural Killer Cells in Leishmaniasis, International Immunopharmacology (2023)